|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.2500 - 0.2600|
|52 Week Range||0.0160 - 0.5400|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER , Aug. 19, 2019 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) is pleased to announce today that its board of directors has appointed Toni Rinow as Chief Executive Officer and Dr. Renz as Regional Manager Europe in addition to serving as its Chief Medical Officer. Under Dr. Toni Rinow's leadership, Pivot will be put on a path of accelerated revenue growth and global expansion in key cannabis markets in Canada , United States , and the European Union.
VANCOUVER , July 9, 2019 /PRNewswire/ - Pivot Pharmaceuticals Inc . (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT ) ("Pivot" or the "Company") announces that it has hired Mr. Russell Starr ...
Pivot will use the remaining proceeds from the non-brokered private placement to execute on product manufacturing, distribution and sales beginning in the European Union, where regulations permit. Further, Pivot will use the proceeds to commence operations in Montreal, Canada where it is working with Health Canada to obtain its Standard Processor and Medical Sales Licenses. Concurrently with the closing of the Offering, Joe Mimran and Dr. Kenneth Kessler joined the Advisory Board of Pivot and Krisztian Toth joined the Board of Directors of Pivot as Executive Chairman and Dr. Joseph Borovsky will serve as the Lead Director.
Pivot's micellized CBD oral solution, is a revolutionary product for the emerging cannabis industry. SolMic's CEO, Dr. Wolfgang Schoenfeld stated, "The entire SolMic team is thrilled to be working with Pivot Pharma. Production of the miCelleBD oral solution has been initiated and our sales and marketing team has begun to take orders from clients, including from a network of 2,000 pharmacies in Germany and Switzerland .
Each Unit consists of one common share of the Company ("Common Share") and one Common Share purchase warrant of the Company ("Warrant"). Each whole Warrant shall be exercisable for a period of two years from the closing date of the Offering to purchase one Common Share at a price of $0.35 per Common Share.
The private placement will be of units at a price of $0.25 per unit, with each unit consisting of one common share and one common share purchase warrant ("Warrants") having a term of two years and an exercise price of $0.35 . The private placement is expected to close in two tranches, with the first closing of $5 million within two weeks and the second tranche of $10 million closing within four weeks. Upon completion of the non-brokered private placement Pivot will issue 60,000,000 units to HPK. Completion of the private placement is conditional on HPK satisfactorily completing its due diligence investigation and High Park Ventures and Pivot entering into an advisory agreement pursuant to which High Park Ventures will provide Pivot with strategic advice.
Pharmascience is the 4th largest manufacturer of over-the-counter generic drugs in the country and is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. Pivot's CEO, Dr. Patrick Frankham stated, "We are thrilled that Pharmascience has agreed to collaborate with Pivot as we prepare to commercialize our bio-cannabis product line.
As previously disclosed, Pivot has invested significantly in the acquisition and licensing of patented drug delivery technologies, developed differentiated cannabis formulations using pharmaceutical grade CBD and THC isolates as active ingredients, and worked with our network of pharma product experts to create the largest catalogue of bioavailable, stable and effective cannabis products. All of Pivot's products will be marketed under "Pivot Naturals" brand, will be manufactured at cGMP accredited facilities in Canada , California and the EU, and will be distributed direct-to-consumer in Canada via Shopify. "Pivot will leverage the full power of Shopify's e-commerce platform to create a state-of-the-art, online destination for consumers in Canada seeking our quality bio-cannabis products. Shopify's unique, industry-leading platform solutions will enable Pivot's brands to seamlessly interact with our new customers, allowing us to accelerate other growth aspects of our business," stated Pivot's CEO, Dr. Patrick Frankham .
The global legal cannabis market is projected to hit $146.4 billion by end of 2025, according to research by Grand View Research. The legal cannabis industry is gaining traction worldwide due to high demand among consumers for recreational and medical products. Recreational cannabis spending is projected to hit $35 Billion mark, while medical cannabis spending […] The post Cannabis Stock News Daily Roundup November 29 appeared first on Market Exclusive.
Pivot Naturals LLC Awarded Temporary License to Manufacture Adult and Medicinal Use Cannabis from the California Department of Public Health